Plasma protease C1-inhibitor treatment involves the administration of concentrated human C1-inhibitor extracted and purified from pooled human plasma to patients suffering from angioedema attacks. C1-inhibitor is a protein produced naturally in the body and helps regulate certain inflammatory and vascular permeability pathways by inhibiting enzymes of the complement, contact, and coagulation systems. The global demand for plasma protease C1-inhibitor treatment has risen in recent years due to increasing prevalence of hereditary angioedema (HAE), a genetic disorder characterized by recurrent episodes of swelling.
The Global plasma protease C1-inhibitor Treatment Market Demand is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the plasma protease C1-inhibitor treatment are R.D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. These major players are focusing on developing innovative plasma protease C1-inhibitor concentrates with improved efficacy and extended shelf-life to expand their market share.
The market offers lucrative growth opportunities with increasing adoption of subcutaneous self-administration of plasma protease C1-inhibitor concentrates. This allows for on-demand treatment and improved accessibility.
Recent advancements in protease C1-inhibitor replacement therapy include the development of second-generation plasma protease C1-inhibitor concentrates with higher purity and specific activity. This helps achieve better treatment response and outcomes for angioedema patients.
Market Drivers
A key growth driver for the plasma protease C1-inhibitor treatment market is the rising awareness regarding hereditary angioedema and availability of effective C1-inhibitor replacement therapy options. As more patients get diagnosed, demand for plasma protease C1-inhibitor concentrates is increasing significantly. Growing research into novel drug formulations is also expanding the therapeutic potential of plasma protease C1-inhibitor treatment in managing other clinical indications like sepsis, acute lung injuries etc. This is anticipated to boost market revenues over the forecast period.
Current challenges in Plasma Protease C1-inhibitor Treatment Market:
The Plasma Protease C1-inhibitor Treatment Market faces various challenges. High costs associated with medication and therapy are a major concern. As the conditions that require this treatment are usually chronic, patients need to undergo therapy cycles repeatedly. This pushes up treatment costs considerably. Other challenges include lack of awareness about available treatment options and limited research funding for finding new treatment methods. Difficulty in procuring donor plasma required for manufacturing drugs also poses a production challenge.
SWOT Analysis
Strength: Existing drugs have well-established efficacy and safety profiles. Growing medical infrastructure and support further boosts access to treatment.
Weakness: High dependence on plasma collection raises raw material supply issues. Lack of therapeutic alternatives restricts treatment options.
Opportunity: Rising incidence of hereditary angioedema presents scope for market growth. New drug delivery methods and plasma fractionation technologies can optimize production.
Threats: Stringent regulations on plasma collection and drug approvals delay product launches. Patent expiries of major drugs enable generic competition.
Geographically, North America currently accounts for the largest share of the global Plasma Protease C1-inhibitor Treatment Market, in terms of value. This is attributed to favorable reimbursement policies and growing healthcare expenditure in the region. Asia Pacific is projected to witness the fastest growth during the forecast period owing to rising medical tourism, tax incentives for setting up manufacturing plants, and growing incidence of target diseases.
The Western European region also holds significant market share and is expected to maintain its position through 2030. Factors such as robust healthcare infrastructure, availability of advanced treatment options, and major company presence drive the Plasma Protease C1-inhibitor Treatment Market in these regions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
